

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	17/LO/1468	230232	A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment	No		30			22/01/2018	25/07/2018	13/11/2017	22/08/2018	24/08/2018		24/08/2018	F - No patients seen	Neither
2	17/NW/0546	228365	A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma	No		7			05/12/2017	10/09/2018	05/12/2017	07/09/2018	17/09/2018		17/09/2018	F - No patients seen	Neither
3	15/NS/0113	188563	The clinical and cost effectiveness of surgical interventions for stones in the lower kidney: The PuRE RCT Percutaneous Nephrolithotomy (PNL), Flexible Ureterorenoscopy (FURS) and Extracorporeal Lithotripsy (ESWL) for lower pole Kidney stones	No		30			19/04/2018	11/09/2018	09/06/2016	17/10/2018	11/10/2018		06/11/2018	F - No patients seen	Neither
4	18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPagliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No		38			20/04/2018	18/09/2018	26/04/2018	16/10/2018	26/10/2018		26/10/2018	F - No patients seen	Neither
5	18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation: a multicentre randomised controlled trial	No		22			26/04/2018	11/10/2018	13/02/2018	19/12/2018	02/11/2018		08/01/2019	D - Sponsor Delays	Sponsor
6	17/SW/0127	225959	A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate	No		38			26/07/2018	01/10/2018	03/07/2017	06/11/2018	08/11/2018		20/11/2018	D - Sponsor Delays	Sponsor
7	16/YH/0225	198518	Interactive Binocular Treatment (I-BIT) for the management anisometropic, strabismic and mixed amblyopia in children aged 3.5-9 years.	No		12			29/06/2018	15/11/2018	10/08/2016	12/10/2018	27/11/2018		27/11/2018	F - No patients seen	Neither
8	18/EM/0270	232477	The effectiveness of a physical activity intervention versus pulmonary rehabilitation on cardiovascular risk markers for individuals with Chronic Obstructive Pulmonary Disease(PARC)	No		18			29/08/2018	15/11/2018	02/11/2018	03/12/2018	03/12/2018		03/12/2018	F - No patients seen	Neither
9	18/SC/0400	245748	A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma	No		6			02/02/2018	27/11/2018	16/10/2018	20/11/2018	03/12/2018		20/12/2018	B - Suspended by sponsor	Sponsor
10	18/EM/0217	244390	Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Heart Failure with Reduced Ejection Fraction	No		34			28/02/2018	08/11/2018	12/09/2018	11/10/2018	12/12/2018		14/01/2019	D - Sponsor Delays	Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
11	18/LO/0204	216147	A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy	Yes	25/06/2019	13	218	231	24/10/2017	06/11/2018	13/04/2018	26/11/2018	19/11/2018		03/12/2018	D - Sponsor Delays	Sponsor
12	18/EM/0119	244650	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Yes	19/02/2019	2	187	189	11/12/2017	14/08/2018	06/07/2018	09/08/2018	16/08/2018		16/08/2018	F - No patients seen	Neither
13	17/WM/0110	212527	Paediatric Hepatic International Tumour Trial	No		37			15/02/2017	11/12/2018	28/04/2017	13/12/2018	17/01/2019		01/02/2019	D - Sponsor Delays	Sponsor
14	17/SC/0661	227234	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	Yes	27/06/2019	46	153	199	30/01/2018	10/12/2018	23/01/2018	14/11/2018	25/01/2019		31/01/2019	J - Other	NHS Provider
15	18/WM/0025	233804	Sub-acromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery	No		16			19/09/2018	22/01/2019	13/02/2018	11/02/2019	07/02/2019		15/02/2019	I - Rare diseases	Neither
16	18/WS/0073	242354	A Randomized, Double-Blind, Placebo Controlled Study To Evaluate Efficacy And Safety Of NEFECON In Patients With Primary IGA Nephropathy At Risk Of Progressing To End-Stage Renal Disease (NeflgArd)	Yes	21/03/2019	11	234	245	25/08/2017	19/07/2018	04/06/2018	02/07/2018	30/07/2018		30/07/2018	F - No patients seen	Neither
17	18/SC/0037	234222	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Yes	20/02/2019	2	146	148	21/10/2017	25/09/2018	16/04/2018	11/09/2018	27/09/2018		27/09/2018	F - No patients seen	Neither
18	18/EM/0298	251419	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis	No		11			25/09/2018	11/02/2019	21/11/2018	14/01/2019	22/02/2019		11/03/2019	F - No patients seen	Neither
19	18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura	No		15			13/08/2018	11/02/2019	11/06/2018	15/11/2018	26/02/2019			F - No patients seen	Neither
20	18/EM/0184	233744	Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)	No		16			28/11/2018	12/02/2019	04/09/2018	18/02/2019	28/02/2019		05/03/2019	F - No patients seen	Neither

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
21	18/YH/0055	241341	A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant.	No		56			06/04/2018	19/12/2018	10/05/2018	07/02/2019	13/02/2019		26/02/2019	D - Sponsor Delays Contracting delays	H - Sponsor
22	18/LO/1706	252196	A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 (PIZZ or null genotype/phenotype) antitrypsin deficiency.	No		82			06/09/2018	13/12/2018	30/11/2018	18/02/2019	05/03/2019		06/03/2019	F - No patients seen	Neither
23	18/LO/0122	238790	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Yes	25/03/2019	13	130	143	07/09/2018	02/11/2018	30/04/2018	01/11/2018	15/11/2018		15/11/2018	F - No patients seen	Neither
24	18/EM/0310	239782	C-Stich2: Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth: a Randomised Controlled Trial	No		36			10/12/2018	05/02/2019	16/11/2018	27/02/2019	13/03/2019		14/03/2019	I - Rare diseases	Neither
25	18/EM/0118	217815	Mesothelioma Stratified Therapy (MIST): A stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma. MIST 1 Rucaparib	Yes	29/01/2019	7	103	110	28/02/2018	11/10/2018	05/07/2018	15/10/2018	18/10/2018		28/01/2019	D - Sponsor Delays	Sponsor
26	18/LO/1606	250789	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera	No		16			28/11/2018	06/03/2019	05/10/2018	08/03/2019	22/03/2019			D - Sponsor Delays	Sponsor
27	18/EE/0296	250366	A Phase I, Open Label, Randomized, Parallel Group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sk+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥ 40 and ≥ 70 mL/min/1.73m ²	No		40			03/09/2018	13/02/2019	18/01/2019	19/02/2019	25/03/2019		04/04/2019	F - No patients seen	Neither
28	18/WA/0236	245863	Acute Rehabilitation following Traumatic anterior shoulder dislocation	Yes	22/05/2019	81	103	184	09/03/2018	19/11/2018	08/08/2018	23/11/2018	08/02/2019		08/02/2019	I - Rare diseases	Sponsor
29	16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)	No		33			14/11/2017	22/02/2019	11/01/2017	20/03/2019	27/03/2019			F - No patients seen	Neither

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
30	18/NE/0125	238346	A three-arm randomised controlled trial to assess the effectiveness and cost-effectiveness of reverse shoulder arthroplasty versus hemiarthroplasty versus non-surgical care for acute three and four-part fractures of the proximal humerus in patients over 65 years of age ? Proximal Fracture Of the Humerus: Evaluation by Randomisation trial No.2 (PROFHER-2).	Yes	29/05/2019	104	93	197	08/12/2017	13/11/2018	15/05/2018	11/02/2019	25/02/2019		25/02/2019	D - Sponsor Delays Rare diseases	I - Sponsor
31	16/NW/0620	206738	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECTCORRECTION)	No		1			14/12/2018	01/04/2019	17/11/2016	20/03/2019	02/04/2019		11/04/2019	F - No patients seen	Neither
32	17/LO/1060	187783	RANDOMISED DOUBLE-BLIND EFFICACY AND MECHANISM STUDY OF SUB-SENSORY SACRAL (OPTIMISED) NEUROMODULATION IN ADULTS WITH FAECAL INCONTINENCE	Yes	12/02/2019	31	82	113	23/04/2018	22/10/2018	29/09/2017	01/11/2018	22/11/2018		27/11/2018	F - No patients seen	Neither
33	16/ES/0110	207747	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	Yes	07/02/2019	65	77	142	08/05/2017	18/09/2018	12/01/2017	07/11/2018	22/11/2018		19/12/2018	D - Sponsor Delays	Sponsor
34	18/WA/0092	230113	Phase II multi-centre, double-blind, randomised trial of Ustekinumab in adolescents with new-onset type 1 diabetes	Yes	24/05/2019	1	80	81	04/10/2018	04/03/2019	21/09/2018	11/02/2019	05/03/2019		01/04/2019	D - Sponsor Delays	Sponsor
35	18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours.	Yes	05/02/2019	8	125	133	07/09/2017	25/09/2018	14/06/2018	25/09/2018	03/10/2018		03/10/2018	F - No patients seen	Neither
36	18/EM/0326	252819	A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma controller (CASCADE)	Yes	02/04/2019	48	103	151	29/08/2018	02/11/2018	17/12/2018	14/12/2018	20/12/2018		14/02/2019	I - Rare diseases	Sponsor
37	18/WA/0247	249407	VIVO Accuracy Study	Yes	05/12/2018	19	64	83	06/03/2018	13/09/2018	10/08/2018	02/10/2018	02/10/2018		02/10/2018	F - No patients seen	Neither
38	18/EM/0166	246673	A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus fumigatus infection in subjects with moderate to severe asthma	Yes	28/01/2019	21	110	131	06/10/2017	19/09/2018	21/08/2018	02/10/2018	10/10/2018		10/10/2018	F - No patients seen	Neither
39	18/WS/0060	241305	Persistence of inflammation and study of T2 pathways following inhibition of Interleukin-5 with Mepolizumab in severe eosinophilic asthma	Yes	03/06/2019	6	61	67	02/11/2018	28/03/2019	31/10/2018	25/03/2019	03/04/2019		30/04/2019	F - No patients seen	Neither
40	16/SW/0232	201854	Rifaximin to Reduce Infection in Decompensated Cirrhosis	No		43			07/08/2018	19/03/2019	31/10/2016		01/05/2019			D - Sponsor Delays Rare diseases	I - Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
41	18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallelgroup, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost-effectiveness trial with internal pilot (A2B Trial)	Yes	12/04/2019	57	56	113	04/10/2018	20/12/2018	14/12/2018	22/01/2019	15/02/2019		08/04/2019	D - Sponsor Delays Rare diseases	I - Sponsor
42	18/LO/1522	249494	A prospective, randomised, double-blind, placebo-controlled, multicentre, phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease.	Yes	19/02/2019	7	91	98	02/08/2018	13/11/2018	06/11/2018	15/11/2018	20/11/2018		17/12/2018	F - No patients seen	Neither
43	17/EM/0121	221773	A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF INHALED NEBULISED PORACTANT ALFA (PORCINE SURFACTANT, CUROSURF?) IN COMPARISON WITH nCPAP ALONE	Yes	18/06/2019	31	53	84	03/09/2018	26/03/2019	22/05/2017	16/04/2019	26/04/2019		17/06/2019	D - Sponsor Delays	Sponsor
44	18/LO/0712	241782	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)	Yes	18/10/2018	13	70	83	24/03/2018	27/07/2018	15/06/2018	12/07/2018	09/08/2018		09/08/2018	F - No patients seen	Neither
45	18/EM/0190	243165	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome	Yes	08/01/2019	67	49	116	11/07/2018	14/09/2018	14/09/2018	05/11/2018	20/11/2018		21/11/2018	F - No patients seen	Neither
46	16/SW/0154	204891	The STAR trial: Evaluation of a care pathway for patients with long-term pain after knee replacement	Yes	01/11/2018	31	55	86	26/06/2017	07/08/2018	04/08/2016	30/08/2018	07/09/2018		07/09/2018	F - No patients seen	Neither
47	19/EM/0031	254100	Understanding the Electrophysiological Substrate in Persistent Atrial Fibrillation - II (USURP AF-study II)	No		44			03/10/2018	02/04/2019	14/02/2019	16/05/2019	16/05/2019		17/05/2019	F - No patients seen	Neither
48	18/WM/0324	246654	FORCE - Forearm fracture Recovery in Children Evaluation: A multi-centre prospective randomized equivalence trial of a soft bandage and immediate discharge versus current treatment with rigid immobilisation for torus fractures of the distal radius in children	Yes	20/01/2019	16	44	60	01/11/2018	21/11/2018	16/11/2018	03/12/2018	07/12/2018		16/01/2019	F - No patients seen	Neither
49	18/EM/0254	246009	A RANDOMISED CONTROLLED TRIAL OF A PRE-OPERATIVE HIGH ENERGY DIET FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: THE PRE-OP ENERGY TRIAL	Yes	07/05/2019	69	41	110	13/03/2018	17/01/2019	27/11/2018		27/03/2019		28/03/2019	H - Contracting delays	Sponsor
50	18/LO/0034	238090	An open-label randomized, parallel-group, multicenter, observational trial to evaluate the safety and efficacy of edoxaban tosylate in children from 38 weeks gestational age to less than 18 years of age with cardiac disease at risk of thromboembolic events.	Yes	03/12/2018	36	73	109	25/04/2018	16/08/2018	29/04/2018	11/09/2018	21/09/2018		23/10/2018	F - No patients seen	Neither

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
51	18/EE/0197	246434	A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	No		18			20/11/2018	02/05/2019	10/08/2018	23/04/2019	20/05/2019		03/06/2019	F - No patients seen	Neither
52	16/LO/1318	187932	Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B)	Yes	03/06/2019	69	61	130	22/11/2018	24/01/2019	21/09/2016	28/03/2019	03/04/2019		12/04/2019	H - Contracting delays	Sponsor
53	18/EE/0092	235968	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and post menopausal women with COPD and muscle weakness, participating in home exercise	Yes	30/10/2018	18	88	106	24/05/2017	16/07/2018	25/05/2018	12/07/2018	03/08/2018		03/08/2018	F - No patients seen	Neither
54	18/LO/0543	242259	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours.	No		8			22/01/2019	14/05/2019	12/06/2018	17/05/2019	22/05/2019		03/06/2019	F - No patients seen	Neither
55	18/EM/0185	243153	Investigating the acute effect of alternative forms of physical activity in a multi-ethnic population: The Yoga Study	Yes	30/10/2018	27	33	60	30/04/2018	31/08/2018	16/08/2018	27/09/2018	27/09/2018		27/09/2018	F - No patients seen	Neither
56	18/EM/0188	246126	A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: THE Val-CARD TRIAL	Yes	21/11/2018	2	33	35	13/03/2018	17/10/2018	23/08/2018	04/10/2018	19/10/2018		19/10/2018		
57	19/YH/0026	256695	A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRX-4DP0004 (a lyophilised formulation of Bifidobacterium breve proprietary strain of 4D Pharma Research) in participants taking long-term control medication for their asthma	No		9			19/02/2019	20/05/2019	09/04/2019	16/05/2019	29/05/2019				
58	18/SS/0131	248427	A Randomised Controlled Trial to investigate the effectiveness of Thoracic Epidural and Paravertebral Blockade In reducing Chronic Post- Thoracotomy Pain: 2	Yes	11/02/2019	2	32	34	03/10/2018	08/01/2019	15/11/2018	04/01/2019	10/01/2019		22/01/2019		
59	18/EM/0336	251477	A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VrD) with VELCADE, Lenalidomide, and Dexamethasone (VRD) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Yes	07/05/2019	4	57	61	31/05/2018	07/03/2019	19/12/2018	04/03/2019	11/03/2019		13/03/2019		

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
60	18/EE/0282	249797	AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Yes	01/04/2019	27	84	111	30/04/2018	11/12/2018	29/10/2018	18/12/2018	07/01/2019		07/01/2019		
61	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/-intervention on outcomes in patients with non ST-elevation myocardial infarction	Yes	06/11/2018	19	28	47	30/08/2018	20/09/2018	12/09/2018	09/10/2018	09/10/2018		09/10/2018		
62	18/EM/0218	245395	Upregulating the Nitric oxide pathway To Restore Autonomic Phenotype (UNTRAP). A double blind randomised first proof of concept? direct translational study to explore the effects of dietary nitrate supplementation on autonomic function in heart failure patients	Yes	25/09/2018	17	26	43	16/03/2018	13/08/2018	09/08/2018	30/08/2018	30/08/2018		30/08/2018		
63	17/SC/0021	219693	The effects of combining electrical stimulation of the calf and thigh muscles in patients with osteoarthritis of the knee	No		5			21/03/2018	03/05/2019	09/03/2017	02/05/2019	08/05/2019		14/05/2019		
64	19/EM/0112	259565	Proof-of-mechanism study of QAW039 (fevipirant) in eosinophilic COPD	No		46			25/03/2019	22/04/2019	21/05/2019	03/06/2019	07/06/2019		12/06/2019	H - Contracting delays	Sponsor
65	18/EE/0099	239606	An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidates for intensive therapy (SOLSTICE study)	No		38			19/12/2018	16/04/2019	01/06/2018	13/05/2019	24/05/2019				
66	17/EM/0440	230556	DANTE: A randomised phase III trial to evaluate the Duration of ANTI-PD1 monoclonal antibody Treatment in patients with metastatic melanoma	No		43			05/02/2018	29/04/2019	18/01/2018	29/05/2019	11/06/2019			H - Contracting delays	Sponsor
67	19/WA/0028	233655	Brain TV (Tissue Velocimetry) for emergency assessment of acquired brain injury	No		19			01/09/2018	23/05/2019	16/05/2019	06/06/2019	11/06/2019				
68	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	No		0			15/01/2019	11/06/2019	17/06/2019	06/06/2019	11/06/2019				
69	18/LO/2113	240789	Outcomes in children referred for chronic cough and clinical markers for presence of bronchiectasis	Yes	01/02/2019	0	18	18	21/09/2018	14/01/2019	09/01/2019	14/01/2019	14/01/2019		14/01/2019		
70	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSANTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY	Yes	01/03/2019	6	30	36	17/07/2018	24/01/2019	04/10/2018	12/11/2018	30/01/2019		06/02/2019		

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
71	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Yes	04/12/2018	0	49	49	11/06/2018	16/10/2018	18/09/2018	05/10/2018	16/10/2018		16/10/2018		
72	19/LO/0285	256948	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)	No		0			04/10/2018	13/05/2019	30/04/2019	07/05/2019	13/05/2019		16/05/2019		
73	18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.	No		208			12/09/2018	22/11/2018	12/06/2018	31/05/2019	18/06/2019			J - Other	NHS Provider
74	18/YH/0322	226765	Single Use Negative Pressure Dressing for Reduction in Surgical Site Infection following Emergency Laparotomy	No		36			18/12/2018	13/05/2019	10/10/2018	13/05/2019	18/06/2019			H - Contracting delays	
75	18/SW/0097	241379	Pre-ATNEC - Preoperative tattooing of biopsied axillary node in breast cancer and correlation to sentinel lymph nodes in breast cancer patient	Yes	18/02/2019	59	10	69	18/10/2018	11/12/2018	23/04/2018	08/02/2019	08/02/2019		14/02/2019		
76	19/YH/0097	261131	Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)	No		7			25/02/2019	13/06/2019	28/05/2019	17/06/2019	20/06/2019				
77	18/EM/0189	244758	A randomised placebo-controlled trial of anti-ST2 in COPD (COPD-ST2OP)	Yes	22/10/2018	0	20	20	27/04/2018	02/10/2018	10/08/2018	10/10/2018	02/10/2018		10/10/2018		
78	18/YH/0396	250694	The Cognition and Flow Study: The Effects of Brain Training on Brain Blood Flow	Yes	22/01/2019	5	8	13	14/08/2018	09/01/2019	08/01/2019	10/01/2019	14/01/2019		14/01/2019		
79	18/WA/0154	233884	WHITE & COPAL: A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture.	Yes	01/10/2018	66	7	73	08/05/2018	20/07/2018	10/05/2018	20/08/2018	24/09/2018		24/09/2018	H - Contracting delays	Sponsor
80	17/NW/0637	229352	BiOMarkers in Urine, antiHypertensive treatment and blood pressure Control in Hypertensive patients - OUTREACH Study	Yes	27/03/2019	20	6	26	22/12/2017	01/03/2019	20/12/2017	08/03/2019	21/03/2019		26/03/2019		
81	16/NW/0621	206740	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PROTECT-CONVERSION)	No		1			14/12/2018	01/04/2019	21/10/2016	20/03/2019	02/04/2019		11/06/2019		
82	18/NE/0296	248487	Carvedilol versus variceal Band ligation in primary prevention of variceal bleeding in liver cirrhosis	No		0			11/09/2018	24/06/2019	19/10/2018	05/03/2019	24/06/2019				
83	19/EM/0027	256620	The efficacy of Transcutaneous Electrical Nerve Stimulation versus local anaesthetic cream in alleviating the pain of local anaesthetic injections in adults - A Randomised Controlled Trial	No		71			07/12/2018	15/04/2019	12/03/2019	25/06/2019	25/06/2019		25/06/2019	D - Sponsor Delays	Sponsor

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
84	18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Yes	12/03/2019	16	20	36	13/06/2018	04/02/2019	03/01/2019	07/02/2019	20/02/2019		25/02/2019		
85	19/LO/0361	258316	Bioimpedence In Pregnancy and Labour: A fluid balance concept study (BIPAL study)	Yes	16/04/2019	19	8	27	07/01/2019	20/03/2019	20/03/2019	08/04/2019	08/04/2019		08/04/2019		
86	19/EE/0014	256539	A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POLYANGIITIS (MPA)	No		26			01/06/2018	08/05/2019	02/05/2019	21/05/2019	03/06/2019		05/06/2019		
87	19/NW/0158	259931	SCIENCE Surgery or Cast for Injuries of the Epicondyle in Children? Elbows: A multicentre prospective randomised superiority trial of operative fixation versus non-operative treatment for medial epicondyle fractures of the humerus in children.	No		20			13/03/2019	07/06/2019	25/03/2019	11/06/2019	27/06/2019				
88	16/NW/0727	187851	Multi Centre RCT of a group psychological intervention for postnatal depression in british mothers of south asia origin - ROSHNI-2 (The word Roshni means light? in Urdu/Hindi)	No					27/04/2018	13/08/2018	06/01/2017					J - Other	Sponsor
89	18/EM/0120	237879	Study 16113 (0146): This is a phase 3, randomized, global, open-label, efficacy and safety study of REGN2810/chemo-f versus REGN2810/chemo-l/ipi versus standard-of-care platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous NSCLC, whose tumors express PD-L1 in <50% of tumor cells (measured using the PD-L1 IHC 22C3 pharmDx assay) and who have received no prior systemic treatment for their advanced disease.	No					03/02/2018	04/12/2018	19/07/2018					J - Other	Sponsor
90	18/LO/2140	246772	Post-Market Study to evaluate Real-world outcomes and treatment Practices for the CENTERA? Transcatheter Heart Valve (THV) System	No					01/10/2018	01/02/2019	01/02/2019					H - Contracting delays	Sponsor
91	19-NI/0037	250757	A phase 1, open-label, single dose, non-randomized study to evaluate pharmacokinetics, pharmacodynamics, and safety of Brixaban in pediatric patients.	No					13/02/2019	31/03/2019	26/03/2019					H - Contracting delays	Sponsor
92	17/SC/0536	216069	A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.	No					31/01/2019	28/05/2019	04/12/2017						

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
93	19/SW/0041	260477	A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008)	No					19/12/2018	10/06/2019	02/04/2019	21/06/2019					
94	19/YH/0049	258945	A PHASE Ic, MULTICENTER, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF A SINGLE DOSE OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER	No					04/02/2018	11/06/2019	30/05/2019						
95	18/LO/0165	224726	POLEM: Avelumab plus 5-FU based chemotherapy as adjuvant treatment for stage 3 MSI-High or POLE exonuclease domain mutant colon cancer: A phase 3 randomised study.	No					22/05/2017	13/06/2019	09/05/2018						
96	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease	No					03/07/2018	17/06/2019	01/10/2018	25/06/2019					
97	19/EM/0057	257429	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	No					22/10/2018	20/06/2019	08/05/2019	17/06/2019					
98	18/LO/0513	230722	A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon beta-la) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm	No					02/05/2017	21/06/2019	10/10/2018						
99	15/WA/0392	169633	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	No					13/04/2018	24/06/2019	15/06/2016						
100	17/LO/0980	219505	Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	No					22/02/2018	25/06/2019	10/07/2017						

Rno	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
101	19/SC/0151	253737	SMARTHEART validation study - A study to assess the accuracy and validate novel smartphone and wearable ECG devices in cardiovascular patients	No					13/11/2018	25/06/2019	17/05/2019						